Well, at least we were able to pick up some shares below 6 again.<g>
Biomira announced yesterday that it has closed the enrollment in the Phase III THERATOPE(R) vaccine trial, and at the time of closure, enrollment had surpassed the 1,000 patient mark. (more than 100 of the 900 originally planned).
"The closing of Biomira's Phase III THERATOPE(R) vaccine trial signifies that we are one important step closer to our goal of commercializing our lead immunotherapeutic product," commented Alex McPherson, MD, PhD, President and CEO.
"We are encouraged by the rapid increase in patient entry over the last few months of the trial. This suggests patients and investigators are enthusiastic about our approach to fighting cancer."
Does anybody think the INVESTIGATORS may have already seen some "miraculous results" as it has been spread out in some rumors ? If if it is true there has been some unusual results already, it could be in the group receiving placebo, after all the "placebo effect" is sometimes strong.<g>
The THERATOPE(R) vaccine Phase III trial is a survival trial with final analysis of data expected to commence in mid-2003.
However, Biomira has planned TWO INTERIM ANALYSES for the THERATOPE(R) vaccine trial to take advantage of the potential to make this product candidate available to cancer patients AS SOON AS POSSIBLE, should statistical significance be seen at either of these two points.
The FIRST of these analyses is anticipated to be initiated in the THIRD QUARTER of 2001.
The precise timing of the first interim analysis, as well as the second and the final analyses are dependent upon a statistical model that requires a pre-determined number of events in each of the two primary endpoints (disease
progression and survival).
BIOM's stock has performed pretty good in spite of the general market's condition and with the presentation in Arizona next week and the ASCO meeting in early May, it is possible that it may weather the present storm even without announcing that they have signed a new "partner".
Now if that FIRST LOOK at the results of Phase III are good, you may be glad you picked up some shares below 6 <g>
Bernard |
